BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15186735)

  • 1. Induction of apoptosis and effect on CD20+ using rituximab on autologous peripheral blood stem cell harvests from patients with B cell lymphomas.
    Borbolla-Escoboza JR; Leon MI; Collados MT; Baez E; Baltasar S; Hernández R; Rojas JC
    Stem Cells Dev; 2004 Apr; 13(2):193-6. PubMed ID: 15186735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo purging of B lymphoma cells from stem-cell products using anti-CD20 Abs.
    Derigs HG
    Cytotherapy; 2000; 2(6):445-53. PubMed ID: 12044225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo purging with rituximab prior to collection of stem cells for autologous transplantation in chronic lymphocytic leukemia.
    Berkahn L; Simpson D; Raptis A; Klingemann HG
    J Hematother Stem Cell Res; 2002 Apr; 11(2):315-20. PubMed ID: 11983102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
    Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
    Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.
    Belhadj K; Delfau-Larue MH; Elgnaoui T; Beaujean F; Beaumont JL; Pautas C; Gaillard I; Kirova Y; Allain A; Gaulard P; Farcet JP; Reyes F; Haioun C
    Ann Oncol; 2004 Mar; 15(3):504-10. PubMed ID: 14998857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
    Vega MI; Huerta-Yepez S; Jazirehi AR; Garban H; Bonavida B
    Oncogene; 2005 Dec; 24(55):8114-27. PubMed ID: 16103877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
    Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
    Seliem RM; Freeman JK; Steingart RH; Hasserjian RP
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
    Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
    Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD20 monoclonal antibodies: beyond B-cells.
    Avivi I; Stroopinsky D; Katz T
    Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
    Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ
    Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
    Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
    Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
    Kanaji N; Ishibashi K; Uno H; Hino N
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells.
    Shan D; Gopal AK; Press OW
    Clin Cancer Res; 2001 Aug; 7(8):2490-5. PubMed ID: 11489831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow experts are still debating the value of purging.
    Benowitz S
    J Natl Cancer Inst; 2000 Feb; 92(3):190-2. PubMed ID: 10655432
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.
    van Heeckeren WJ; Vollweiler J; Fu P; Cooper BW; Meyerson H; Lazarus HM; Simic A; Laughlin MJ; Gerson SL; Koç ON
    Br J Haematol; 2006 Jan; 132(1):42-55. PubMed ID: 16371019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.